Analysis of the difference in SLCO1B1 and APOE gene polymorphisms between Mongolian and Han populations
Abstract
Objective: To analyze SLCO1B1 and APOE polymorphisms and their clinical significance in the Mongolian and Han populations in Ordos, Inner Mongolia. Methods: Mongolian patients (n = 200) with cardiovascular disease admitted to our hospital from January 2018 to December 2020 were selected as the Mongolian population group. Han patients (n = 200) with cardiovascular diseases admitted during the same period were selected as the Han population group. Mutations in SLCO1B1 and APOE were detected by real-time fluorescence qPCR, and the differences between the two groups were analyzed. Results: The nucleotide polymorphisms of SLCO1B1 and APOE in the Mongolian and Han populations were consistent with the Hardy–Weinberg law. There were significant differences in gender, age, BMI, hypertension, alcohol consumption, dyslipidemia and low-density lipoprotein cholesterol levels between the two groups. APOE genotypes were classified according to those related to the efficacy of statins and the risk of atherosclerosis, and there was a significant difference between the two groups. Conclusion: There were differences in SLCO1B1 and APOE polymorphisms between the Mongolian and Han populations in Ordos. These may explain the differences in the incidence of cardiovascular diseases and the lipid-lowering efficacy of statins between the two populations.
References
- 1. Clustering of cardiovascular risk factors and diabetes: a prospective cohort study on the Inner Mongolian population in China. Biomed. Environ. Sci. 31(10), 749–756 (2018).
- 2. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J. Am. Coll. Cardiol. 72(25), 3233–3242 (2018).
- 3. Pharmacogenetics of statins treatment: efficacy and safety. J. Clin. Pharm. Ther. 44(6), 858–867 (2019 Dec).
- 4. . Effects of structural and genetic polymorphisms on the pharmacokinetics of statins. Chin. J. Pharm. 53(1), 6–9 (2018).
- 5. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J. Clin. Lab. Anal. 32(6), e22408 (2018).
- 6. . Guidelines for the Diagnosis and Treatment of Cardiovascular Internal Diseases (3rd Edition). Science Press, Beijing, China, 75–116 (2013).
- 7. Distribution of SLCO1B1 and APOE gene polymorphisms in Han Chinese patients with cardiovascular disease in Anhui Province and their significance in the clinical individualization of statins. Chinese Clinical Pharmacology and Therapeutics. 26(1), 40–48 (2021).
- 8. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revised edition). Chin. J. Health Manage. 11(1), 7–28 (2017).
- 9. Joint Committee on the Revision of the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revised edition). Chin. J. Circ. 31, 937–950 (2016).
- 10. . Statins personalized. Med. Clin. North Am. 96(1), 123–139 (2012).
- 11. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur. J. Clin. Pharmacol. 71(3), 341–355 (2015).
- 12. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case–control studies. Medicine (Baltimore) 94(37), e1268 (2015).
- 13. Association of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population. J. Diabetes Complications 29(8), 1191–1197 (2015).
- 14. . Correlation analysis of APOE and SLCO1B1 gene polymorphisms with ischemic stroke. Stroke Neurol. Dis. 25(3), 264–267, 271 (2018).
- 15. . Relationship between SLCO1B1 and apolipoprotein E gene polymorphisms and blood lipids in patients with atherosclerotic cardiovascular disease risk stratification. Chin. J. Geriatr. Cardiovasc. Dis. 20(7), 676–680 (2018).
- 16. Study on the relationship between SLCO1B1 and APOE gene polymorphisms and the risk of coronary heart disease in the Mongolian population. Clin. Exp. Hypertens. 43(8), 788–792 (2021).
- 17. Analysis of SLCO1B1 and APOE gene polymorphisms and clinical significance in Han Chinese population in central China. J. Pract. Med. 34(18), 3041–3046 (2018).
- 18. Analysis of APOE and SLCO1B1 gene polymorphisms in Han Chinese patients with cardiovascular and cerebrovascular diseases in Hebei. Chin. J. Mod. Neurol. Dis. 21(5), 400–405 (2021).
- 19. ApolipoproteinE and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 9(2), 106–18 (2013).
- 20. Distribution of APOE polymorphism in Chinese Yunnan Dehong Dai ethnic group. Chin. J. Med. Genet. 22(2), 224–226 (2005).
- 21. Correlation of APOE and SLCO1B1 gene polymorphisms and genotype with lipid levels in Gansu. Chin. Heart J. 1, 46–49 (2019).
- 22. Analysis of statin-related gene polymorphisms and clinical significance in Han Chinese population in Hainan. Int. J. Geriatr. 42(3), 143–147; 176 (2021).
- 23. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am. J. Cardiol. 111(8), 1221–1229 (2013).
- 24. Study on the distribution status of apolipoprotein E gene polymorphisms in different populations. Chin. J. Physicians 2(9), 530–531, 534 (2000).